Hims & Hers Surges on Novo Obesity Deal That Ends Public Feud Hims & Hers Health Inc. saw its stock price rise sharply after Novo Nordisk A/S agreed to end its public dispute with the company through a new partnership. The deal involves Novo Nordisk’s weight-loss medications being sold on the Hims platform, marking a resolution to their ongoing conflict. According to a source familiar with the matter, the two companies plan to formally announce the partnership on Monday. This agreement follows a similar deal from last year, which Novo abruptly canceled after Hims continued marketing and selling generic versions of Novo’s drugs. The feud had drawn significant attention, with both companies accusing each other of unfair practices. The new partnership is expected to address these tensions by allowing Novo to distribute its obesity treatments through Hims’s digital health platform. This move could expand access to weight-loss medications for patients while providing Hims with additional revenue streams. Analysts suggest the deal reflects a broader trend of pharmaceutical companies seeking to leverage digital health platforms to reach consumers directly. The resolution of the public feud has also bolstered investor confidence in Hims & Hers, contributing to its stock surge. The company has long positioned itself as a leader in the digital wellness space, offering products ranging from hair loss treatments to sexual health solutions. With the addition of Novo’s obesity drugs, Hims aims to strengthen its portfolio and compete more effectively in the crowded health tech market. The partnership underscores the growing importance of digital platforms in healthcare, as companies seek to bypass traditional distribution channels and engage consumers directly.#hims_hers #novonordisk #hims_hers_health_inc #hims #novonordisk_as
